Aisling’s Schiff on life sciences investing and today’s investment cycleByMark Boslet29 May 2018•4 mins readJavaScript is required to read this article. Please enable it in your browser and reload the page.FeaturedManagersFeaturedHealthcarePeople - FirmsPeople News